Congrats Amandeep Godara on a great presentation on LOS using the NIS! Andreas Klein, MD Tufts Medical Center

Congrats to Aman @myelomAman_md -2nd year in a row we had the opportunity to present our work at #TCTM19 @CIMBTR ASBMT Oral presentation, Poster ASCT - LOS Transplant related TTP

#ASTCT19 President Indus BMT Group dinner

Congrats Tania!!

Big guns at ASTCT19 #gun show @ same convention center #onlyinTexas

Congratulations Aman Godara for the 3rd consecutive oral presentation at #TCT #ASTCT #Legacy #tradition Andreas Klein, MD @BldCancerDoc Hilal Hachem Andrew M. Evens, DO, MBA, MSc @WasifSaifMD @SaurabhDahiyaMD

Interesting story in the Times about the forensic implications of hematopoietic cell transplantation... although one of the experts they quoted sounds pretty dodgy. 😇 nytimes.com/2019/12/07/us/…

#ASH19 #MachineLearning Using ML algorithms and state level data base to predict acute myeloid leukemia treatment related in hospital mortality, independent of type of chemotherapy, performance status and disease characteristics.

Fruit of labor from 1st year of fellowship!!!

Just out. We analyzed inpatient transplant outcomes and factors predicting variations in hospital stay for allo-transplant Ankit kansagra Rishi Dhawan ऋषि धवन

Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post–Kidney Transplant: A Case Report buff.ly/3kgAqoD #OpenAccess Nitender Goyal @Gordon7Craig Tufts Medical Center #kidneytransplant #PKD

Stem-cell source, acute GVHD, infections, and hospital size most significant factors associated with LOS for allogenic stem-cell transplant fal.cn/39RnA #JCOOP

More data from Tufts Medical Center and @sloan_kettering on importance of post-treatment iFLC in AL #Amyloidosis: The lower, the better!! tinyurl.com/y25vje3u Amyloidosis Support

pubmed.ncbi.nlm.nih.gov/33068021/ Aman Godara

Review Article: Myeloproliferative neoplasms: from origins to outcomes owl.li/PC4c30h3Ig4

DREAMM-1 Monotherapy with GSK2857916, Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Impressive activity. 60% response rate. PFS ~8 months. Time will tell how this compares to BCMA CAR-T. Glad to have both options. #ASH17 #ASH17VR ash.confex.com/ash/2017/webpr… 👇

A CAR-T to cure CD19 CAR-T related B cell aplasia. #ASH17 poster 4463. A CAR-T to kill CAR-Ts.

Is this the future (in addition to CARs ofcourse): Venetoclax + anything = better RR (except in Follicular😉)? #ASH17

Summary slides by Alan Wayne - Role of CTL in post BMT relapse Rx . #ASH17

2017 a banner year for FDA approvals in hematologic malignancies. In this graphic, purple=4 new drug approvals for AML; red=5 new drugs for ALL/NHL; orange=supplemental approvals for new indications #ASH17